SEOUL, June 13 (Reuters) - South Korea’s Hanwha Chemical said on Monday it had won a license deal worth $720 million for its biosimilar product with Merck Sharp & Dohme Research Ltd, a subsidiary of U.S. drug firm Merck & Co .
The contract will cover global sales of the licensed product excluding South Korea and Turkey and will last until the end of 2024, Hanwha said in a statement. (Reporting by Miyoung Kim; Editing by Ken Wills)
